June 4, 2023

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Tsuboi et al. (Sun,) studied this question.

synapsesocial.com/papers/6941cf2d6ff23261fafbb7c7 https://doi.org/https://doi.org/10.1056/nejmoa2304594

Preguntar a la IA

Me gusta

Guardar